期刊文献+

国产吉西他滨联合5-氟尿嘧啶治疗晚期胰腺癌临床观察 被引量:2

Domestic gemcitabine and 5 fluorouracil treatment for advanced pancreatic cancer
下载PDF
导出
摘要 目的:观察国产吉西他滨联合5-氟尿嘧啶治疗晚期胰腺癌临床疗效及不良反应。方法:19例晚期胰腺癌患者随机分为两组,观察组10例,给予GCF方案(吉西他滨联合5-氟尿嘧啶),21天为1周期;对照组9例,给予FAM方案(5-氟尿嘧啶联合阿霉素、丝裂霉素),21天为1周期,均至少化疗2周期。结果:19例患者均可评价疗效和不良反应。临床受益反应率明显优于对照组(50%vs22%,P<0.05);观察组中位生存期和1年生存率也明显优于对照组(P<0.05);主要不良反应为白细胞下降、胃肠道反应,均较对照组轻,其它不良反应两组相似均可耐受。结论:吉西他滨联合5-氟尿嘧啶治疗晚期胰腺癌近期临床疗效较高,不良反应可以耐受。 Objective:To observe the effect of domestic gemcitabine and 5 -fluorouracil treatment for advanced pancreatic cancer. Methods:Nineteen patients with advanced pancreatic cancer patients were randomly divided into two groups, the observer group 10 cases treated with GCF programme (gemcitabine and 5 -fluorouracil), a cycle of 21 days for the control group nine cases, given FAM programme (5 -fluorouracil combined doxorubicin, silk out Adriamycin) ,for a period of 21 days,at least two cycles. Results:All 19 patients can be evaluated. Clinical benefit response rate was superior to the control group (50% vs 22% P 〈0.05) ;observer group in the median survival time and one - year survival rate was significantly better than the control group ( P 〈 0.05 ) ; major adverse reactions were leukopenia, stomach reaction,light than the control group, other adverse reactions can be tolerated. Conclusion:Gemcitabine and 5 - fluorouracil treatment for advanced pancreatic cancer is effective the recent high, adverse reactions can be tolerated.
出处 《现代肿瘤医学》 CAS 2009年第5期898-899,共2页 Journal of Modern Oncology
关键词 5-氟尿嘧啶 吉西他滨 联合化疗 晚期胰腺癌 5 - fluorouracil gemcitabine combined chemotherapy advanced pancreatic cancer
  • 相关文献

参考文献7

二级参考文献40

  • 1龚德根,郑鸿.健择联用HCPT治疗胰腺癌的临床观察[J].中华腹部疾病杂志,2003,3(8):570-571. 被引量:1
  • 2Burris HA, Moore M J, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [J]. J Clin Oncol, 1997, 15(6):2403-2413.
  • 3Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of report of randomized clinical trials: Is blinding necessary [J].Controlled Clin Trials, 1996, 17:1-12.
  • 4Scheithauer W, Schull B, Ulrich-Pur H, et al. Biweekly highdose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase Ⅱ trial [J]. Ann Oncol, 2003, 14(1) :97-104.
  • 5Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective,randomized phase Ⅲ study of the Gruppo Oncologia dell'Italia Meridionale [J]. Cancer, 2002, 94(4):902-910.
  • 6Gansauge F, Ramadani M, Pressmar J, et al. NSC-631570(Ukrain) in the palliative treatment of pancreatic cancer.Results of a phase Ⅱ trial [J]. Langenbecks Arch Surg, 2002,386(8): 570-574.
  • 7Berlin JD, Catalano P, Thomas JP, et al. Phase Ⅲ study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 [J]. J Clin Oncol,2002, 20(15): 3270-3275.
  • 8Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer [J]. Br J Cancer, 2002, 87(2): 161-167.
  • 9Van Cutsem E, van de Velde H, Karasek P, et al. Phase ⅢTrial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer [J]. JClin Oncol, 2004, 22(8):1430-1438.
  • 10Louvet C, Labianca R, Hammel P, et al. GemOx (gemcitabine+oxaliplatin) versus Gem (gemcitabine) in non resectable pancreatic adenocarcinoma: Final results of the GERCOR/GISCAD Intergroup Phase Ⅲ [J]. J Clin Oncol, 2004, 22(14suppl): abstr 4008.

共引文献428

同被引文献13

  • 1虞先浚,蒋永剑,傅德良,倪泉兴.胰腺癌中胸苷磷酸化酶和二氢嘧啶脱氢酶含量及其比值的测定[J].中华肿瘤杂志,2004,26(10):618-620. 被引量:9
  • 2赵玉沛.中国胰腺癌治疗20年的成绩和需研究的问题[J].外科理论与实践,2007,12(3):193-195. 被引量:35
  • 3孙燕 宋少章.临床肿瘤内科手册[M].北京:人民卫生出版社,1991.23.
  • 4Burris H A,Moore M J,Andersen J,et al.Improvements in survival and clinical benefit with gemcitabine as first-time therapy for patients with advanced pancreas cancer:arandomized tria.J Clin Oncol,1997,15(6):2403.
  • 5Milandri C,Calzolari F,Passardi A,et al.Intra Chemotherapy of Advanced Pancreatic.Cancer:a Single Ceter Experience.Hepatogastroenterology,2007,54(80):2373.
  • 6David C,Ian c.Phase III randomized comparison of gemcit-abine versus gemcitabine plus capecitabine in patients with ad-vanced pancreatic cancer[J].J Clin Oncol,2009,27(33):5513.
  • 7Pelzer U,Kubica K,Stieler J,et al.A randomized trial inpatients with gemcitabine refractory pancreatic cancer.Final re-sults of the CONCO 003 study[J].J Clin Oncol,2008,26(May20suppl):4508.
  • 8Cartwright TH,Cohn A,Varkey JA,et al.Phase II study oforal capecitabine in patients with advanced or metastatic pancreat-ic cancer[J].J Clin Oncol,2002,20(1):160.
  • 9Saif MW.New developments in the treatment of the pancre-atic cancer.Highlights from the 44th ASCO AnnualMeeting.Chicago,IL,USA.May 30-June 3,28[J].JOP,2008,9(4):391.
  • 10Terashima M,Fujiwara H,Takaganc A,et al.Role of thymi-dine phosphorylasc and dihydropyrimidinc dechydagenasc intumour progression and sensitivit to doxifluridine in gastric cancerpatients[J].Eur J Cancer,2002,38(18):2375.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部